{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=51", "query": { "intervention": "Open Label Extension Study", "page": 51 }, "page_size": 10 }, "pagination": { "page": 51, "page_size": 10, "total_count": 2085, "total_pages": 209, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=52&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=50&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T19:49:13.534Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07682961", "title": "Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lenacapavir", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Teropavimab", "type": "DRUG" }, { "name": "Zinlirvimab", "type": "DRUG" }, { "name": "Cabotegravir", "type": "DRUG" }, { "name": "Rilpivirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-07-14", "completion_date": "2033-03", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 16, "location_summary": "San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami Gardens", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07682961" }, { "nct_id": "NCT03794583", "title": "Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Hypertension", "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Inhaled treprostinil solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-12-21", "completion_date": "2022-11-29", "has_results": true, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Sacramento, California • Clearwater, Florida + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03794583" }, { "nct_id": "NCT01999894", "title": "Open-label Study of Safety and Tolerability of Memantine in Children With Autism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism", "Pediatric Autism" ], "interventions": [ { "name": "Memantine HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Years to 18 Years" }, "enrollment_count": 102, "start_date": "2009-11", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-03-18", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01999894" }, { "nct_id": "NCT00835770", "title": "BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-Remitting Multiple Sclerosis" ], "interventions": [ { "name": "dimethyl fumarate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "58 Years", "sex": "ALL", "summary": "19 Years to 58 Years" }, "enrollment_count": 1736, "start_date": "2009-02-03", "completion_date": "2019-11-08", "has_results": true, "last_update_posted_date": "2020-12-31", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00835770" }, { "nct_id": "NCT06679881", "title": "Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema (HAE)" ], "interventions": [ { "name": "Deucrictibant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharvaris Netherlands B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 170, "start_date": "2025-02-01", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06679881" }, { "nct_id": "NCT07033494", "title": "A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early Alzheimer's Disease" ], "interventions": [ { "name": "MK-2214", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 340, "start_date": "2025-07-16", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 36, "location_summary": "Irvine, California • Long Beach, California • Los Angeles, California + 32 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07033494" }, { "nct_id": "NCT01252186", "title": "A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemostasis", "Oral Contraceptive" ], "interventions": [ { "name": "91-day Levonorgestrel Oral Contraceptive", "type": "DRUG" }, { "name": "28-day Levonorgestrel Oral Contraceptive", "type": "DRUG" }, { "name": "28-day Desogestrel Oral Contraceptive", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Women's Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 265, "start_date": "2010-11", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2015-03-13", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 21, "location_summary": "San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252186" }, { "nct_id": "NCT04747613", "title": "Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Paroxysmal Nocturnal Hemoglobinuria" ], "interventions": [ { "name": "Iptacopan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 208, "start_date": "2021-07-27", "completion_date": "2027-10-18", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04747613" }, { "nct_id": "NCT02881320", "title": "Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "B/F/TAF (Adult Strength)", "type": "DRUG" }, { "name": "B/F/TAF (Low Dose)", "type": "DRUG" }, { "name": "B/F/TAF (TOS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 177, "start_date": "2016-09-21", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 10, "location_summary": "Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02881320" }, { "nct_id": "NCT05869669", "title": "RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dementia With Lewy Bodies" ], "interventions": [ { "name": "Neflamapimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EIP Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 159, "start_date": "2023-05-01", "completion_date": "2025-06-16", "has_results": true, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-11-06T19:49:13.534Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05869669" } ] }